Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i>-Mutant Advanced Non–Small Cell Lung Cancer

A. Jänne, Pasi; M. van den Heuvel, Michel; Barlési, Fabrice; Cobo, Manuel; Mazières, Julien; Crinò, Lucio; В. Орлов, С.; Blackhall, Fiona; Wolf, Juergen; Garrido, Pilar; Poltoratskiy, Artem; Mariani, G; Ghiorghiu, Dana; Kilgour, Elaine; D. Smith, Paul; Kohlmann, Alexander; Carlile, David; Lawrence, David; Bowen, Karin; Vansteenkiste, Johan

doi:10.1001/jama.2017.3438

Public

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

Published in JAMA • May 9, 2017

Authors:

Pasi A. Jänne

Michel M. van den Heuvel

Fabrice Barlési

Abstract

Importance: There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. Objective: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with ...

Subject

Medicine

Docetaxel

Selumetinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!